跳至主要内容
临床试验/NL-OMON26137
NL-OMON26137招募中不适用

B cell monitoring in young and elderly healthy donors, young smokers, elderly smokers and patients with stable coronary artery disease

CHDR0 个研究点目标入组 150 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
CHDR
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • Healthy volunteers:
  • 1. healthy male subjects (18-25 years or >60 years);
  • 2. ability to participate, and willingness to give written informed consent and to comply with the study restrictions.
  • 3. BMI 18 - 28
  • 4. non-smoking, elderly non-smoking for at least 15 years.
  • 1. male subjects (18-25 years or >45 years)
  • 2. ability to participate, and willingness to give written informed consent and to comply with the study restrictions.
  • 3. BMI 18 - 28
  • 4. volunteers >45 years: smoking for at least 15 packyears, volunteers 18- 25 years: at least ½ pack a day for 6 months.
  • CAD patients:
  • 1. male patients (>60 years) with proven stable atherosclerotic coronary artery disease defined as having undergone a revascularization procedure followed by a period of at least one year without signs or symptoms of coronary artery disease;
  • 2. having one of the following risk factors: high cholesterol, smoking, diabetes, hypertension, or familiar risk.
  • 3. ability to participate, and willingness to give written informed consent and to comply with the study restrictions.
  • 4. BMI 18 - 28

排除标准

  • Healthy volunteers:
  • 1. evidence of any active or chronic disease or condition (based on medical history, a physical examination, and vital signs) that could, in the opinion of the investigator, interfere with the study objectives;
  • 2. evidence of any active or chronic disease or condition that affects the immune system.
  • 3. having one of the following risk factors for CAD: high cholesterol, smoking, diabetes, hypertension, or familiar risk.
  • 4. the use of any medication or vitamin/mineral/herbal/dietary supplement within less than 5 half-lives prior to study participation is prohibited, if the Investigator judges that it may interfere with the study objectives. The use of paracetamol (up to 4 g/day) is allowed;
  • 5. body weight < 50 kg; BMI <18 or >28.
  • 6. subject is pregnant or breast feeding;
  • 7. smoking or current substance abuse, including alcohol and drugs;
  • 8. loss or donation of blood over 500 mL within three months prior to participation;
  • 9. unwillingness or inability to comply with the study protocol for any other reason.
  • 1. evidence of any active or chronic disease or condition (based on medical history, a physical examination, and vital signs) that could, in the opinion of the investigator, interfere with the study objectives;
  • 2. body weight < 50 kg; or BMI <18 or >35;
  • 3. substance abuse, including alcohol and drugs;
  • 4. loss or donation of blood over 500 mL within three months prior to participation;
  • 5. unwillingness or inability to comply with the study protocol for any other reason.
  • CAD patients:
  • 1. evidence of any active or chronic disease or condition other than stable CAD (based on medical history, a physical examination, and vital signs) that could, in the opinion of the investigator, interfere with the study objectives;
  • 2. evidence of any active or chronic disease or condition other than stable CAD that affects the immune system.
  • 3. body weight < 50 kg; BMI <18 or >28.
  • 4. substance abuse, including alcohol and drugs;
  • 5. loss or donation of blood over 500 mL within three months (males) prior to participation;
  • 6. unwillingness or inability to comply with the study protocol for any other reason.

研究者

发起方
CHDR

相似试验